,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Mr. Chen  Schor BA, CPA, CPA, M.B.A., MBA', 'age': 50, 'title': 'CEO, Pres & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 899576, 'exercisedValue': 0, 'unexercisedValue': 1843}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
1,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Dr. Aya  Jakobovits Ph.D.', 'age': 67, 'title': 'Founder & Independent Director', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
2,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Dr. Blake  Aftab Ph.D.', 'age': 41, 'title': 'Sr. VP & Chief Scientific Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 675039, 'exercisedValue': 0, 'unexercisedValue': 22015}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
3,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Dr. Francesco  Galimi M.D., Ph.D.', 'age': 54, 'title': 'Chief Medical Officer & Sr. VP', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 680365, 'exercisedValue': 0, 'unexercisedValue': 266029}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
4,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Mr. Brian Nicholas Harvey', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
5,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Dr. Donald  Healey Ph.D.', 'age': 60, 'title': 'Chief Technology Officer', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
6,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Ms. Amy  Locke', 'title': 'Head of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
7,200 Berkeley Street,19th Floor,Boston,MA,02116,United States,650 503 9095,https://www.adicetbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.",132,"{'maxAge': 1, 'name': 'Dr. Nancy L. Boman M.D., Ph.D.', 'title': 'Sr. VP & Chief Regulatory Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,8,8,1693526400,1672444800,86400,4,1.79,1.68,1.7,1.851,1.79,1.68,1.7,1.851,0.0,1.580203,-0.6218182,577602,577602,962600,499440,499440,1.63,1.85,900,1200,73643200,1.6,21.87,Infinity,2.2999,6.239925,0.0,0.0,USD,-109174872,0.0,26933145,43066200,2697094,2299310,1690761600,1693440000,0.0626,0.03319,0.96068,4.92,0.0847,43066200,5.551,0.3080526,1672444800,1703980800,1688083200,-115154000,-2.8,-2.75,-0.02,1:7,1600214400,0.924,-0.8786373,0.14113986,NGM,EQUITY,ACET,ACET,"Adicet Bio, Inc.","Adicet Bio, Inc.",1516977000,America/New_York,EDT,65920c5d-73a6-39e2-8917-c1ab3dd20f9e,finmb_310073311,-14400000,1.71,28.0,10.0,20.33,21.5,2.0,buy,6,205460000,4.771,-118179000,22642000,10.94,11.076,0,9.471,0.0,-0.25258,-0.43264,24990000,-66664500,-83158000,0.0,0.0,0.0,USD,
